Noom is entering the off-label weight loss drug market, combining behavioral programs with prescription options.
Rachel Mahoney has been appointed as Noom's Chief Brand Officer to enhance brand strategy.
Noom's compounded GLP-1 product reflects its response to rising obesity and high drug prices.